- Home
- FINW vs CMPX Comparison
FINW vs CMPX Comparison
Compare FINW & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINW | CMPX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 752.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | FINW | CMPX |
|---|---|---|
| Price | $18.10 | $5.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $21.67 | $13.44 |
| AVG Volume (30 Days) | 13.9K | ★ 1.9M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $80,198,000.00 | N/A |
| Revenue This Year | $72.14 | N/A |
| Revenue Next Year | $47.30 | N/A |
| P/E Ratio | $16.92 | ★ N/A |
| Revenue Growth | ★ 14.76 | N/A |
| 52 Week Low | $13.49 | $1.33 |
| 52 Week High | $22.49 | $5.86 |
Technical Indicators
Market Signals| Indicator | FINW | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 55.26 |
| Support Level | $17.30 | $5.09 |
| Resistance Level | $18.14 | $5.44 |
| Average True Range (ATR) | 0.39 | 0.34 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 43.39 | 41.59 |
Price Performance
Historical ComparisonAbout FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.